Literature DB >> 12650001

Obligation to advise of options for treatment--medical doctors and complementary and alternative medicine practitioners.

Michael Weir1.   

Abstract

An important aspect of health professional's duty of care is to advise patients of the available options of treatment so that the patient can choose the form of treatment that suits her or his requirements. As CAM becomes more evidence-based and accepted, medical doctors need to consider the extent to which they should provide patients with information about those types of treatments. If a CAM treatment option is evidence-based, there is a strong argument that medical doctors should advise of this option for treatment to satisfy their duty. CAM practitioners should also provide details of options for treatment within their own modality but are not obliged to advise of medical options.

Entities:  

Mesh:

Year:  2003        PMID: 12650001

Source DB:  PubMed          Journal:  J Law Med        ISSN: 1320-159X


  4 in total

1.  Responding to GPs' information resource needs: implementation and evaluation of a complementary medicines information resource in Queensland general practice.

Authors:  Tina Janamian; Stephen P Myers; Peter O'Rourke; Heather Eastwood
Journal:  BMC Complement Altern Med       Date:  2011-09-20       Impact factor: 3.659

2.  Talking to cancer patients about complementary therapies: is it the physician's responsibility?

Authors:  M J Verhoef; H S Boon; S A Page
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

3.  'PICO-D Management'; a decision-aid for evidence-based chiropractic education and clinical practice.

Authors:  Lyndon G Amorin-Woods; Barrett E Losco
Journal:  Chiropr Man Therap       Date:  2016-12-12

4.  "Part of the Conversation": A Qualitative Study of Oncology Healthcare Professionals' Experiences of Integrating Standardized Assessment and Documentation of Complementary Medicine.

Authors:  Lynda G Balneaves; Cody Z Watling
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.